Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function
dc.contributor.author | Hauck, Paula M. | |
dc.contributor.author | Wolf, Eric R. | |
dc.contributor.author | Olivos, David J., III | |
dc.contributor.author | Batuello, Christopher N. | |
dc.contributor.author | McElyea, Kyle C. | |
dc.contributor.author | McAtarsney, Ciaran | |
dc.contributor.author | Cournoyer, R. Michael | |
dc.contributor.author | Sandusky, George E. | |
dc.contributor.author | Mayo, Lindsey D. | |
dc.contributor.department | Pediatrics, School of Medicine | en_US |
dc.date.accessioned | 2018-05-17T16:52:40Z | |
dc.date.available | 2018-05-17T16:52:40Z | |
dc.date.issued | 2017-11 | |
dc.description.abstract | Metastasis of cancer cells to distant organ systems is a complex process that is initiated with the programming of cells in the primary tumor. The formation of distant metastatic foci is correlated with poor prognosis and limited effective treatment options. We and others have correlated Mouse double minute 2 (Mdm2) with metastasis; however, the mechanisms involved have not been elucidated. Here, it is reported that shRNA-mediated silencing of Mdm2 inhibits epithelial–mesenchymal transition (EMT) and cell migration. In vivo analysis demonstrates that silencing Mdm2 in both post-EMT and basal/triple-negative breast cancers resulted in decreased primary tumor vasculature, circulating tumor cells, and metastatic lung foci. Combined, these results demonstrate the importance of Mdm2 in orchestrating the initial stages of migration and metastasis. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Hauck, P. M., Wolf, E. R., Olivos, D. J., Batuello, C. N., McElyea, K. C., McAtarsney, C. P., … Mayo, L. D. (2017). Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function. Molecular Cancer Research, 15(11), 1598–1607. https://doi.org/10.1158/1541-7786.MCR-17-0174 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/16210 | |
dc.language.iso | en | en_US |
dc.publisher | AACR | en_US |
dc.relation.isversionof | 10.1158/1541-7786.MCR-17-0174 | en_US |
dc.relation.journal | Molecular Cancer Research | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | Mdm2 | en_US |
dc.subject | EMT | en_US |
dc.subject | metastisis | en_US |
dc.title | Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function | en_US |
dc.type | Article | en_US |